583 related articles for article (PubMed ID: 9475764)
1. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera.
Moliterno AR; Hankins WD; Spivak JL
N Engl J Med; 1998 Feb; 338(9):572-80. PubMed ID: 9475764
[TBL] [Abstract][Full Text] [Related]
2. A novel thrombopoietin signaling defect in polycythemia vera platelets.
Moliterno AR; Siebel KE; Sun AY; Hankins WD; Spivak JL
Stem Cells; 1998; 16 Suppl 2():185-92. PubMed ID: 11012190
[TBL] [Abstract][Full Text] [Related]
3. Signal transduction in platelets from patients with polycythemia vera.
Lange W; Martens UM; Waller CF
N Engl J Med; 1998 Jul; 339(2):127-8. PubMed ID: 9669902
[No Abstract] [Full Text] [Related]
4. Thrombopoietin receptor (Mpl) expression by megakaryocytes in myeloproliferative disorders.
Bock O; Schlué J; Mengel M; Büsche G; Serinsöz E; Kreipe H
J Pathol; 2004 May; 203(1):609-15. PubMed ID: 15095485
[TBL] [Abstract][Full Text] [Related]
5. Polycythemia vera--chance, death, and mutability.
Schwartz RS
N Engl J Med; 1998 Feb; 338(9):613-5. PubMed ID: 9475771
[No Abstract] [Full Text] [Related]
6. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia.
Li J; Xia Y; Kuter DJ
Br J Haematol; 2000 Dec; 111(3):943-53. PubMed ID: 11122159
[TBL] [Abstract][Full Text] [Related]
7. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.
Silva M; Richard C; Benito A; Sanz C; Olalla I; Fernández-Luna JL
N Engl J Med; 1998 Feb; 338(9):564-71. PubMed ID: 9475763
[TBL] [Abstract][Full Text] [Related]
8. Progenitor cell trafficking in physiologic conditions and in myeloproliferative diseases: quantification of CD34+ cells by polymerase chain reaction.
Oppliger Leibundgut E; Brunold C; Marti D; Horn MP; Seiler C; Schroeder V; Schmid JP; Tobler A; Zwicky C
Haematologica; 2005 Jul; 90(7):875-80. PubMed ID: 15996924
[TBL] [Abstract][Full Text] [Related]
9. Etiology of the myeloproliferative disorders: the role of thrombopoietin.
Kaushansky K
Semin Hematol; 2003 Jan; 40(1 Suppl 1):6-9. PubMed ID: 12682875
[TBL] [Abstract][Full Text] [Related]
10. Circulating thrombopoietin in clonal versus reactive thrombocytosis.
Karakuş S; Ozcebe OI; Haznedaroğlu IC; Göker H; Ozatli D; Koşar A; BüyükaşIk Y; Ertuğrul D; SayInalp N; KirazlI S; Dündar SV
Hematology; 2002 Feb; 7(1):9-12. PubMed ID: 12171772
[TBL] [Abstract][Full Text] [Related]
11. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
12. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
Ryningen A; Apelseth T; Hausken T; Bruserud Ø
Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
[TBL] [Abstract][Full Text] [Related]
13. Defective c-Mpl signaling in the syndrome of thrombocytopenia with absent radii.
Ballmaier M; Schulze H; Cremer M; Folman CC; Strauss G; Welte K
Stem Cells; 1998; 16 Suppl 2():177-84. PubMed ID: 11012189
[TBL] [Abstract][Full Text] [Related]
14. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets.
Li J; Sabath DF; Kuter DJ
Cytokine; 2000 Jul; 12(7):835-44. PubMed ID: 10880227
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical staining for megakaryocyte c-mpl may complement morphologic distinction between polycythemia vera and secondary erythrocytosis.
Tefferi A; Yoon SY; Li CY
Blood; 2000 Jul; 96(2):771-2. PubMed ID: 10887148
[TBL] [Abstract][Full Text] [Related]
16. Marked heterogeneity in protein levels and functional integrity of the thrombopoietin receptor c-mpl in polycythaemia vera.
Le Blanc K; Andersson P; Samuelsson J
Br J Haematol; 2000 Jan; 108(1):80-5. PubMed ID: 10651727
[TBL] [Abstract][Full Text] [Related]
17. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin.
Oda A; Miyakawa Y; Druker BJ; Ishida A; Ozaki K; Ohashi H; Wakui M; Handa M; Watanabe K; Okamoto S; Ikeda Y
Blood; 1996 Dec; 88(11):4304-13. PubMed ID: 8943867
[TBL] [Abstract][Full Text] [Related]
18. Quantitative and functional studies of impaired natural killer (NK) cells in patients with myelofibrosis, essential thrombocythemia, and polycythemia vera. I. A potential role for platelet-derived growth factor in defective NK cytotoxicity.
Gersuk GM; Carmel R; Pattamakom S; Challita PM; Rabinowitz AP; Pattengale PK
Nat Immun; 1993; 12(3):136-51. PubMed ID: 8329837
[TBL] [Abstract][Full Text] [Related]
19. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
20. The role of beta-catenin in chronic myeloproliferative disorders.
Jauregui MP; Sanchez SR; Ewton AA; Rice L; Perkins SL; Dunphy CH; Chang CC
Hum Pathol; 2008 Oct; 39(10):1454-8. PubMed ID: 18619646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
